# Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)

> **NCT03889444** · — · COMPLETED · sponsor: **Allergan** · enrollment: 141 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Dexamethasone intravitreal implant

## Key facts

- **NCT ID:** NCT03889444
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-15
- **Primary completion:** 2019-06-07
- **Final completion:** 2019-06-07
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2020-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03889444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03889444, "Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03889444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*